Koninklijke Philips N.V. Q2 2026 Earnings Recap

Shares declined 3.1% as investors reacted negatively to a deceleration in order intake amid continued tariff-related margin pressures, despite stable sales growth and maintained full-year guidance.

Key Takeaways

• Comparable sales grew 4% in Q2, consistent across all segments.
• Adjusted EBITA margin increased to 16.4%, but underlying margin excluding tariff refunds was 12.2%, highlighting ongoing cost and tariff headwinds.
• Order intake declined 1% overall, with Monitoring orders shifting timing into Q3, interrupting a six-quarter growth streak.
• Continued weakness in China impacted Diagnosis & Treatment orders despite strong growth in North America and Europe.
• Full-year comparable sales growth outlook (3% to 4.5%) and underlying EBITA margin guidance (12.5% to 13%) were reiterated, showing a cautious but stable outlook.